Postbiotic Composition Modulating Microbiota to Reduce Chemotherapy Toxicity

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current cancer treatments, such as chemotherapy and radiotherapy, often have high toxicity and side effects, and there is a need for alternative compositions that can effectively modulate the intestinal microbiota to improve the efficacy and safety of cancer therapies, particularly for patients with solid tumors.

Innovation Solution

A postbiotic composition comprising lysates of probiotic microorganisms, specifically 6-19% Bacillus, 4-8% Bifidobacterium, 15-25% Lactobacillus, 50-60% Saccharomyces, and 1.5-5% Streptococcus, which acts as an immunomodulator and angiogenesis modulator, improving the immune response and bioavailability of treatments.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional cancer treatments (chemotherapy, radiotherapy) are used, then tumor eradication effectiveness is improved, but patient body toxicity and side effects worsen

Engineering Contradiction:
Improvetumor eradication effectivenessVSAvoidpatient body toxicity
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces probiotic microorganisms as intermediary agents that mediate between the patient's body and cancer treatments. These probiotics colonize the gastrointestinal tract and modulate the immune system, creating a protective intermediary layer that enhances treatment effectiveness while reducing direct toxicity to the patient's body.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent converts the previously harmful effect of conventional treatments (high toxicity) into a beneficial outcome by using probiotics to counteract and mitigate these toxic effects. The probiotics transform the harmful chemical and radiation exposure into a controlled immune modulation process that protects healthy tissues while maintaining anti-tumor effectiveness.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

2Object-affected harmful factors

If alternative cancer treatments are used, then patient body safety is improved, but treatment effectiveness worsens

Engineering Contradiction:
Improvepatient body safetyVSAvoidtreatment effectiveness
Core Design Contradiction:
Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent applies preliminary action by administering probiotics before and during conventional cancer treatments. This pre-conditioning of the immune system through probiotic colonization prepares the patient's body to better tolerate and respond to subsequent chemotherapy or radiotherapy, ensuring both safety and effectiveness are achieved.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent creates a composite therapeutic approach by combining conventional cancer treatments with probiotic microorganisms. This composite strategy integrates the direct anti-tumor effects of chemotherapy/radiotherapy with the immune-modulating effects of probiotics, resulting in a synergistic treatment that maintains effectiveness while improving safety.

Inventive Principle:
Principle #40Composite materials

3Reliability

If probiotic microorganisms are administered, then immune response modulation is improved, but treatment complexity worsens

Engineering Contradiction:
Improveimmune response modulationVSAvoidtreatment complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs self-service by using probiotic microorganisms that autonomously colonize the gastrointestinal tract and modulate the immune system without requiring complex external control mechanisms. The probiotics self-regulate their population and activity based on environmental conditions, simplifying the treatment protocol while maintaining effective immune modulation.

Inventive Principle:
Principle #25Self-service

Data Source

PatentEP4438050A1Postbiotic composition comprising bacterial lysates for oral administration for treating solid tumors
Publication Date: 2024.10.02 SIGNIFER SL
  • EP4438050A1 patent drawingFigure 1
  • EP4438050A1 patent drawingFigure 2a~2b
  • EP4438050A1 patent drawingFigure 2c~2d

AI summary

The present invention discloses a postbiotic composition for oral administration for use in the treatment of solid tumors in a patient, said composition comprising lysates of probiotic microorganisms of the genera Bacillus; Bifidobacterium; Lactobacillus, Saccharomyces, Streptococcus.